Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model.

abstract：:The molecular events which confer cellular resistance to cytotoxic drugs such as cytosine arabinoside (ara-C) are poorly understood. Nevertheless, in a proportion of patients with acute leukemia, such events will be responsible for the failure of therapy. Mutations which cause ara-C resistance in a chinese hamster ova...

journal_title：Leukemia

authors： Whelan J,Smith T,Phear G,Rohatiner A,Lister A,Meuth M

更新日期：1994-02-01 00:00:00

abstract：:Multiple myeloma (MM) is characterized by bone marrow infiltration with abnormal plasma cells which synthesize monoclonal immunoglobulins (Ig) or Ig fragments. Regularly, MM cells exhibit a high intrinsic resistance to available chemotherapeutic strategies. A number of cellular alterations including the cellular membr...

journal_title：Leukemia

authors： Gieseler F,Nüssler V

更新日期：1997-12-01 00:00:00

abstract：:Chimeric antigen receptor (CAR) T cell therapies lead to high clinical response rates in B cell malignancies, and are under investigation for treatment of solid tumors. While high systemic interleukin- (IL-) 6 levels are associated with clinical cytokine release syndrome (CRS), the role of IL-6 trans-signaling within ...

journal_title：Leukemia

authors： Jiang Z,Liao R,Lv J,Li S,Zheng D,Qin L,Wu D,Chen S,Long Y,Wu Q,Wang S,Lin S,Huang X,Tang Z,Shi P,Zhou H,Liu Q,Zhao R,Li Y,Jie Y,Wei W,Lai P,Du X,Cui S,Weinkove R,Liu P,Pei D,Yao Y,Li P

更新日期：2020-11-09 00:00:00

abstract：:A prospective multicenter study was performed to investigate the clinical and molecular results of intensified double induction therapy including high-dose cytarabine (ara-C) in combination with ATRA in newly diagnosed acute promyelocytic leukemia (APL), followed by consolidation and 3 years maintenance therapy. Fifty...

journal_title：Leukemia

authors： Lengfelder E,Reichert A,Schoch C,Haase D,Haferlach T,Löffler H,Staib P,Heyll A,Seifarth W,Saussele S,Fonatsch C,Gassmann W,Ludwig WD,Hochhaus A,Beelen D,Aul C,Sauerland MC,Heinecke A,Hehlmann R,Wörmann B,Hiddemann

更新日期：2000-08-01 00:00:00

abstract：:Natural killer (NK) cell-type lymphoproliferative diseases of granular lymphocytes can be subdivided into aggressive NK cell leukemia (ANKL) and chronic NK cell lymphocytosis (CNKL). One reason for the poor outcome in ANKL is leukemic infiltration into multiple organs. The mechanisms of cell trafficking associated wit...

journal_title：Leukemia

authors： Makishima H,Ito T,Asano N,Nakazawa H,Shimodaira S,Kamijo Y,Nakazawa Y,Suzuki T,Kobayashi H,Kiyosawa K,Ishida F

更新日期：2005-07-01 00:00:00

abstract：:The EU-supported EuroFlow Consortium aimed at innovation and standardization of immunophenotyping for diagnosis and classification of hematological malignancies by introducing 8-color flow cytometry with fully standardized laboratory procedures and antibody panels in order to achieve maximally comparable results among...

journal_title：Leukemia

authors： Kalina T,Flores-Montero J,van der Velden VH,Martin-Ayuso M,Böttcher S,Ritgen M,Almeida J,Lhermitte L,Asnafi V,Mendonça A,de Tute R,Cullen M,Sedek L,Vidriales MB,Pérez JJ,te Marvelde JG,Mejstrikova E,Hrusak O,Szczepańs

更新日期：2012-09-01 00:00:00

abstract：:Adolescents had lower rates of remission induction and shorter event-free survival than younger children in this study of consecutively treated patients with acute lymphoblastic leukemia (ALL). When compared to the younger patients (ages 1-9 years; n = 995), adolescents (ages 10-21 years; n = 338) were significantly m...

journal_title：Leukemia

authors： Santana VM,Dodge RK,Crist WM,Rivera GK,Look AT,Behm FG,Raimondi SC,Pui CH

更新日期：1990-02-01 00:00:00

abstract：:In order to further define the role of the MDR1 gene in acute myeloid leukemia (AML), we determined the association between the presence of P-glycoprotein on leukemic cells and the efficacy of therapy in patients with AML. Immunocytochemistry with monoclonal antibody C219 was performed to demonstrate the presence of P...

journal_title：Leukemia

authors： Zöchbauer S,Gsur A,Brunner R,Kyrle PA,Lechner K,Pirker R

更新日期：1994-06-01 00:00:00

abstract：:Fas ligand (FasL) is capable of inducing apoptosis of lymphoid cells by cross-linking with its natural receptor, Fas. We aimed to investigate the possible role of the Fas/FasL-mediated apoptosis in the development of human lymphomas. FasL mRNA was detected by reverse transcriptase-polymerase chain reaction in 38 out o...

journal_title：Leukemia

authors： Xerri L,Devilard E,Hassoun J,Haddad P,Birg F

更新日期：1997-11-01 00:00:00

abstract：:The molecular basis for autonomous growth of malignant forms of human T lymphocytes is not known. It can be investigated by functional responses of malignant cells in comparison with untransformed counterparts. At least two pathways (the CD2 and CD3 pathways) of human T-cell activation have been recently defined on th...

journal_title：Leukemia

authors： Schirren CA,Völpel H,Meuer SC

更新日期：1992-06-01 00:00:00

abstract：:Germline CD95 (also known as FAS, APT1 and APO1) gene mutations have been associated with benign lymphoproliferative diseases and autoimmune processes. Somatic mutations have been reported in human tumours, including lymphomas. Since marginal zone B cell lymphomas usually arise in a background of chronic inflammation,...

journal_title：Leukemia

authors： Bertoni F,Conconi A,Luminari S,Realini C,Roggero E,Baldini L,Carobbio S,Cavalli F,Neri A,Zucca E

更新日期：2000-03-01 00:00:00

abstract：:The observation that wild type p53 may induce cells to undergo either apoptosis or differentiation raises the question of whether these two events share similar p53-dependent pathways. To evaluate the interrelationship between these two p53-dependent processes, our study focused on the human HL-60, a pro-myelocytic p5...

journal_title：Leukemia

authors： Rotter V,Ronen D

更新日期：1997-04-01 00:00:00

abstract：:Mesenchymal stem cells (MSC) possess anti-inflammatory properties and participate in tissue repair. We used MSC to heal therapy-induced tissue toxicity. Ten consecutive patients, treated with MSC due to tissue toxicity following allogeneic hematopoietic stem cell transplantation, (ASCT) were included. Their median age...

journal_title：Leukemia

authors： Ringdén O,Uzunel M,Sundberg B,Lönnies L,Nava S,Gustafsson J,Henningsohn L,Le Blanc K

更新日期：2007-11-01 00:00:00

abstract：:p53 is frequently wild type (wt) in diffuse large B-cell lymphoma (DLBCL) associated with t(14;18)(q32;q21) that overexpresses BCL2. Nutlin-3a is a small molecule that activates the p53 pathway by disrupting p53-MDM2 interaction. We show that nutlin-3a activates p53 in DLBCL cells associated with t(14;18)(q32;q21), BC...

journal_title：Leukemia

authors： Drakos E,Singh RR,Rassidakis GZ,Schlette E,Li J,Claret FX,Ford RJ Jr,Vega F,Medeiros LJ

更新日期：2011-05-01 00:00:00

abstract：:In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM...

journal_title：Leukemia

authors： Dimopoulos MA,Leleu X,Palumbo A,Moreau P,Delforge M,Cavo M,Ludwig H,Morgan GJ,Davies FE,Sonneveld P,Schey SA,Zweegman S,Hansson M,Weisel K,Mateos MV,Facon T,Miguel JF

更新日期：2014-08-01 00:00:00

abstract：:This paper describes seven patients with ALL and a hypodiploid karyotype with less than 40 chromosomes. A consideration of these and 15 previously published cases indicates that they may be divided into two groups depending on chromosome number, i.e., less than 30 and 30-39. The less than 30 group are younger and pred...

journal_title：Leukemia

authors： Callen DF,Raphael K,Michael PM,Garson OM

更新日期：1989-10-01 00:00:00

abstract：:FMS-like tyrosine kinase 3 (FLT3) is a transmembrane protein expressed on normal hematopoietic stem and progenitor cells (HSC) and retained on malignant blasts in acute myeloid leukemia (AML). We engineered CD8+ and CD4+ T-cells expressing a FLT3-specific chimeric antigen receptor (CAR) and demonstrate they confer pot...

journal_title：Leukemia

authors： Jetani H,Garcia-Cadenas I,Nerreter T,Thomas S,Rydzek J,Meijide JB,Bonig H,Herr W,Sierra J,Einsele H,Hudecek M

更新日期：2018-05-01 00:00:00

abstract：:The International Acute Lymphoblastic Leukemia Working Group, the so-called 'Ponte di Legno Workshop' has led to substantial progress in international collaboration in leukemia research. On April 27-28, 2005, the 8th Meeting was held in Vienna, Austria, to continue the discussions about special common treatment elemen...

journal_title：Leukemia

authors： Gadner H,Masera G,Schrappe M,Eden T,Benoit Y,Harrison C,Nachman J,Pui CH

更新日期：2006-01-01 00:00:00

abstract：:Burkitt lymphoma (BL) has a characteristic clinical presentation, morphology, immunophenotype and primary chromosomal aberration, that is, the translocation t(8;14)(q24;q32) or its variants. However, diagnostic dilemmas may arise in daily practice due to overlap of BL with subsets of other aggressive, mature B-cell ly...

journal_title：Leukemia

authors： Boerma EG,Siebert R,Kluin PM,Baudis M

更新日期：2009-02-01 00:00:00

abstract：:Depending on disease stage follicular lymphoma (FL) lack the t(14;18) in ~15-~50% of cases. Nevertheless, most of these cases express BCL2. To elucidate mechanisms triggering BCL2 expression and promoting pathogenesis in t(14;18)-negative FL, exonic single-nucleotide variant (SNV) profiles of 28 t(14;18)-positive and ...

journal_title：Leukemia

authors： Zamò A,Pischimarov J,Schlesner M,Rosenstiel P,Bomben R,Horn H,Grieb T,Nedeva T,López C,Haake A,Richter J,Trümper L,Lawerenz C,Klapper W,Möller P,Hummel M,Lenze D,Szczepanowski M,Flossbach L,Schreder M,Gattei V,O

更新日期：2018-03-01 00:00:00

abstract：:Between August 1978 and September 1982, 642 patients with newly diagnosed acute myelogenous leukemia (AML) were entered onto a Southwest Oncology Group Study which addressed four questions. (i) What is the comparative utility of rubidazone versus adriamycin in remission induction? (ii) What is the role of prophylactic...

journal_title：Leukemia

authors： Morrison FS,Kopecky KJ,Head DR,Athens JW,Balcerzak SP,Gumbart C,Dabich L,Costanzi JJ,Coltman CA,Saiki JH

更新日期：1992-07-01 00:00:00

abstract：:Multiple myeloma is a deadly hematopoietic malignancy. Despite therapeutic advances such as autologous stem cell transplantation and novel chemotherapeutics, multiple myeloma remains incurable. Multiple myeloma cell localization in the bone marrow and the cross-talk with the bone niche trigger dramatic alterations in ...

journal_title：Leukemia

authors： Colombo M,Mirandola L,Platonova N,Apicella L,Basile A,Figueroa AJ,Cobos E,Chiriva-Internati M,Chiaramonte R

更新日期：2013-04-01 00:00:00

abstract：:Tumor lysis syndrome (TLS) has been described in over 40% of patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. We conducted a retrospective analysis to determine predictive factors for TLS. In 116 patients, the incidence of TLS was 46% (95% CI: 36-55%). In uni...

journal_title：Leukemia

authors： Blum KA,Ruppert AS,Woyach JA,Jones JA,Andritsos L,Flynn JM,Rovin B,Villalona-Calero M,Ji J,Phelps M,Johnson AJ,Grever MR,Byrd JC

更新日期：2011-09-01 00:00:00

abstract：:A poorly defined transforming event(s) affects the pluripotential bone marrow (BM) stem cell in myelodysplastic syndromes (MDS), conferring a growth advantage upon it which leads eventually to monoclonal hematopoiesis. The progeny of this transformed ancestor undergo recognizable albeit dysplastic maturation. We propo...

journal_title：Leukemia

authors： Raza A,Mundle S,Shetty V,Alvi S,Chopra H,Span L,Parcharidou A,Dar S,Venugopal P,Borok R,Gezer S,Showel J,Loew J,Robin E,Rifkin S,Alston D,Hernandez B,Shah R,Kaizer H,Gregory S,Preisler H

更新日期：1996-10-01 00:00:00

abstract：:We have investigated the activity of ITF2357, a novel hydroxamate histone deacetylase inhibitor, on multiple myeloma (MM) and acute myelogenous leukemia (AML) cells in vitro and in vivo. ITF2357 induced apoptosis in 8/9 MM and 6/7 AML cell lines, as well as 4/4 MM and 18/20 AML freshly isolated cases, with a mean IC(5...

journal_title：Leukemia

authors： Golay J,Cuppini L,Leoni F,Micò C,Barbui V,Domenghini M,Lombardi L,Neri A,Barbui AM,Salvi A,Pozzi P,Porro G,Pagani P,Fossati G,Mascagni P,Introna M,Rambaldi A

更新日期：2007-09-01 00:00:00

abstract：:PRDM1/BLIMP-1, a master regulator of plasma-cell differentiation, is frequently inactivated in activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) patients. Little is known about its genetic aberrations and relevant clinical implications. A large series of patients with de novo DLBCL was effectively eval...

journal_title：Leukemia

authors： Xia Y,Xu-Monette ZY,Tzankov A,Li X,Manyam GC,Murty V,Bhagat G,Zhang S,Pasqualucci L,Visco C,Dybkaer K,Chiu A,Orazi A,Zu Y,Richards KL,Hsi ED,Choi WW,van Krieken JH,Huh J,Ponzoni M,Ferreri AJ,Møller MB,Parsons

更新日期：2017-03-01 00:00:00

abstract：:Therapy for multiple myeloma (MM) has markedly changed in the past decade with the introduction of new drugs, but it is not clear whether the improvements have been sustained. We studied 1038 patients diagnosed between 2001 and 2010, grouping patients into two 5-year periods by diagnosis, 2001-2005 and 2006-2010. The ...

journal_title：Leukemia

authors： Kumar SK,Dispenzieri A,Lacy MQ,Gertz MA,Buadi FK,Pandey S,Kapoor P,Dingli D,Hayman SR,Leung N,Lust J,McCurdy A,Russell SJ,Zeldenrust SR,Kyle RA,Rajkumar SV

更新日期：2014-05-01 00:00:00

abstract：:Human DNA ligase was purified from different kinds of immunocompetent cells: thymocytes, normal and stimulated lymphocytes, blasts from ALL (Burkitt and non-T, non-B) and ANLL (M1, M2, and M5). Based upon the protocol for the treatment of these leukemias, the purified enzymes were assayed in the presence of routinely ...

journal_title：Leukemia

authors： Lamballe F,Maniey D,Boscher MY,Fauchet R,le Prise PY,David JC

更新日期：1988-06-01 00:00:00

abstract：:Multiple myeloma is the second most frequent hematological cancer after lymphoma and remains an incurable disease. The pervasive support provided by the bone marrow microenvironment to myeloma cells is crucial for their survival. Here, an unbiased assessment of receptor tyrosine kinases overexpressed in myeloma identi...

journal_title：Leukemia

authors： Frenquelli M,Caridi N,Antonini E,Storti F,Viganò V,Gaviraghi M,Occhionorelli M,Bianchessi S,Bongiovanni L,Spinelli A,Marcatti M,Belloni D,Ferrero E,Karki S,Brambilla P,Martinelli-Boneschi F,Colla S,Ponzoni M,DePinho R

更新日期：2020-01-01 00:00:00

abstract：:The pH chromosome, resulting from the t(9;22) translocation, is the most frequently observed cytogenetic aberration in acute lymphoblastic leukemia (ALL). Two genes, bcr and abl, are involved in this translocation. As a consequence, parts of the bcr and abl genes are fused, resulting in chimeric bcr-abl genes encoding...

journal_title：Leukemia

authors： van Denderen J,ten Hacken P,Berendes P,Zegers N,Boersma W,Grosveld G,van Ewijk W

更新日期：1994-09-01 00:00:00